Viking Therapeutics stock plunges 37% as trial data sparks concerns over dropout rates and side effects despite weight loss ...

When Opill became available a year ago, public health experts anticipated it would benefit women without health insurance and those residing in rural areas. The goal was to boost access to ...

NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach ...

An outbreak of Legionnaires’ disease in City’s Harlem neighborhood thought to have originated in contaminated cooling towers ...

This episode of Pharma Pulse covers Novo Nordisk’s FDA win for Wegovy in MASH-related liver fibrosis, new research on a ...

Novo said cash-paying Americans can now buy Ozempic for $499 per month through various channels including its official ...

Andersen has a fair value estimate of $71 for Novo stock. Closing around $52.41 on Aug. 15 (near its lowest level since ...

Overview Nifty 50 index closed at 24,986, crossing the 25,000 mark intraday for the first time, while the Sensex settled at ...

The FDA has granted accelerated approval for Wegovy for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults.

FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...

The string of negative updates from Novo Nordisk and positive news flow from the main competitor Eli Lilly has finally ended ...

Plus: Labor’s envoy courts OpenAI, tech giants for local AI centres; Citi takes ten senior JPMorgan bankers in global talent ...